Yüklüyor......
Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management
In the last years the onset of new therapies changed the management of malignant melanoma. Anti CTLA-4 antibody ipilimumab was the first drug to achieve a significant improvement in survival of advanced stage melanoma. This new therapeutic agent is characterized by a number of side effects that are...
Kaydedildi:
| Yayımlandı: | Hum Vaccin Immunother |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Taylor & Francis
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4963052/ https://ncbi.nlm.nih.gov/pubmed/26889818 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2015.1129478 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|